Home > Research Institute > Available Trials > MK-7684A + Etoposide and Platinum for 1st line treatment of Small Cell Lung Cancer
MK-7684A + Etoposide and Platinum for 1st line treatment of Small Cell Lung Cancer
A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer
Disease Types: Lung
Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville
A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer
For more information: